Mesenchymal stromal cells (MSC) emerged as highly attractive in cell-based regenerative medicine. Initially thought to provide cells capable of differentiation towards mesenchymal cell types (osteoblasts, chondrocytes, adipocytes etc.), by and by potent immunoregulatory and pro-regenerative activities have been discovered, broadening the field of potential applications from bone and cartilage regeneration to wound healing and treatment of autoimmune diseases. Due to the limited frequency in most tissue sources, ex vivo expansion of MSC is required compliant with good manufacturing practice (GMP) guidelines to yield clinically relevant cell doses. Though, still most manufacturing protocols use fetal bovine serum (FBS) as cell culture supplement to isolate and to expand MSC. However, the high lot-to-lot variability as well as risk of contamination and immunization call for xenogenic-free culture conditions. In terms of standardization, chemically defined media appear as the ultimate achievement. Since these media need to maintain all key cellular and therapy-relevant features of MSC, the development of chemically defined media is still - albeit highly investigated - only in its beginning. The current alternatives to FBS rely on human blood-derived components: plasma, serum, umbilical cord blood serum, and platelet derivatives like platelet lysate. Focusing on quality aspects, the latter will be addressed within this review.

Keywords:
Mesenchymal stromal cells, Fetal bovine serum, Good manufacturing practice, Platelet lysate, Platelet releasate
1.
Gstraunthaler G: Alternatives to the use of fetal bovine serum: serum-free cell culture. Altex-Altern Tierexp 2003;20:275-281.
2.
Nurden AT: Platelets, inflammation and tissue regeneration. Thromb Haemost 2011;105(suppl 1): S13-33.
3.
Eastment CT, Sirbasku DA: Human platelet lysate contains growth factor activities for established cell lines derived from various tissues of several species. In vitro 1980;16:694-705.
4.
Hara Y, Steiner M, Baldini MG: Platelets as a source of growth-promoting factor(s) for tumor cells. Cancer Res 1980;40:1212-1216.
5.
Choi YC, Morris GM, Sokoloff L: Effect of platelet lysate on growth and sulfated glycosaminoglycan synthesis in articular chondrocyte cultures. Arthritis Rheum 1980;23:220-224.
6.
Dugrillon A, Eichler H, Kern S, Kluter H: Autologous concentrated platelet-rich plasma (cprp) for local application in bone regeneration. Int J Oral Maxillofac Surg 2002;31:615-619.
7.
Rendu F, Brohard-Bohn B: The platelet release reaction: Granules' constituents, secretion and functions. Platelets 2001;12:261-273.
8.
Maynard DM, Heijnen HFG, Horne MK, White JG, Gahl WA: Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost 2007;5:1945-1955.
9.
Jonas JB, Dugrillon A, Kluter H, Kamppeter B: Subconjunctival injection of autologous platelet concentrate in the treatment of overfiltrating bleb. J Glaucoma 2003;12:57-58.
10.
Sommeling CE, Heyneman A, Hoeksema H, Verbelen J, Stillaert FB, Monstrey S: The use of platelet-rich plasma in plastic surgery: A systematic review. J Plast Reconstr Aesthet Surg 2013;66:301-311.
11.
Vavken P, Sadoghi P, Murray MM: The effect of platelet concentrates on graft maturation and graft-bone interface healing in anterior cruciate ligament reconstruction in human patients: a systematic review of controlled trials. Arthroscopy 2011;27:1573-1583.
12.
Sheth U, Simunovic N, Klein G, Fu F, Einhorn TA, Schemitsch E, Ayeni OR, Bhandari M: Efficacy of autologous platelet-rich plasma use for orthopaedic indications: A meta-analysis. The Journal Bone Joint Surg 2012;94:298-307.
13.
Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, Exposito JA, Bolibar I, Rodriguez L, Garcia J: Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev 2012;10:CD006899.
14.
Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ: Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005;205:228-236.
15.
Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92.
16.
Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-247.
17.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
18.
Caplan AI: The mesengenic process. Clin Plast Surg 1994;21:429-435.
19.
Caplan AI: Mesenchymal stem cells. J Orthop Res 1991;9:641-650.
20.
Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A: Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393-395.
21.
Pevsner-Fischer M, Levin S, Zipori D: The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev 2011;7:560-568.
22.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
23.
Schafer R, Northoff H: Characteristics of mesenchymal stem cells - new stars in regenerative medicine or unrecognized old fellows in autologous regeneration? Transfus Med Hemother 2008;35:154-159.
24.
Bourin P, Gadelorge M, Peyrafitte JA, Fleury-Cappellesso S, Gomez M, Rage C, Sensebe L: Mesenchymal progenitor cells: tissue origin, isolation and culture. Transfus Med Hemother 2008;35:160-167.
25.
Bieback K: Basic biology of mesenchymal stem cells. Transfus Med Hemother 2008;35:151-152.
26.
Rojewski MT, Weber BM, Schrezenmeier H: Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother 2008;35:168-184.
27.
Wagner W, Saffrich R, Ho AD: The stromal activity of mesenchymal stromal cells. Transfus Med Hemother 2008;35:185-193.
28.
Bifari F, Lisi V, Mimiola E, Pasini A, Krampera M: Immune modulation by mesenchymal stem cells. Transfus Med Hemother 2008;35:194-204.
29.
Collas P, Noer A, Sorensen AL: Epigenetic basis for the differentiation potential of mesenchymal and embryonic stem cells. Transfus Med Hemother 2008;35:205-215.
30.
Frith J, Genever P: Transcriptional control of mesenchymal stem cell differentiation. Transfus Med Hemother 2008;35:216-227.
31.
Gimble JM, Guilak F, Nuttall ME, Sathishkumar S, Vidal M, Bunnell BA: In vitro differentiation potential of mesenchymal stem cells. Transfus Med Hemother 2008;35:228-238.
32.
Quinn C, Flake AW: In vivo differentiation potential of mesenchymal stem cells: Prenatal and postnatal model systems. Transfus Med Hemother 2008;35:239-247.
33.
Ratajczak MZ, Zuba-Surma EK, Wojakowski W, Ratajczak J, Kucia M: Bone marrow - home of versatile stem cells. Transfus Med Hemother 2008;35:248-259.
34.
Tonn T, Barz D: Msc - a multipotent stromal cell in search of clinical application. Transfus Med He-mother 2008;35:269-270.
35.
Klingemann H, Matzilevich D, Marchand J: Mesenchymal stem cells - sources and clinical applications. Transfus Med Hemother 2008;35:272-277.
36.
Brooke G, Rossetti T, Ilic N, Murray P, Hancock S, Pelekanos R, Atkinson K: Points to consider in designing mesenchymal stem cell-based clinical trials. Transfus Med Hemother 2008;35:279-285.
37.
Bieback K, Schallmoser K, Kluter H, Strunk D: Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med Hemother 2008;35:286-294.
38.
Slaper-Cortenbach IC: Current regulations for the production of multipotent mesenchymal stromal cells for clinical application. Transfus Med Hemother 2008;35:295-298.
39.
Lepperdinger G, Brunauer R, Gassner R, Jamnig A, Kloss F, Laschober GT: Changes of the functional capacity of mesenchymal stem cells due to aging or age-associated disease - implications for clinical applications and donor recruitment. Transfus Med Hemother 2008;35:299-305.
40.
Henschler R, Deak E, Seifried E: Homing of mesenchymal stem cells. Transfus Med Hemother 2008;35:306-312.
41.
Lindner U, Kramer J, Rohwedel J, Schlenke P: Mesenchymal stem or stromal cells: toward a better understanding of their biology? Transfus Med Hemother 2010;37:75-83.
42.
Bernardo ME, Pagliara D, Locatelli F: Mesenchymal stromal cell therapy: a revolution in regenerative medicine? Bone Marrow Transplant 2012;47:164-171.
43.
Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
44.
Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
45.
Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O: Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733-1738.
46.
Prockop DJ: ‘Stemness' does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCS). Clin Pharmacol Ther 2007;82:241-243.
47.
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
48.
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
49.
Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K: No alloantibodies against mesenchymal stromal cells, but presence of antifetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007;92:1208-1215.
50.
Caplan AI, Correa D: The MSC: an injury drugstore. Cell Stem Cell 2011;9:11-15.
51.
Bianco P, Barker R, Brustle O, Cattaneo E, Clevers H, Daley GQ, De Luca M, Goldstein L, Lindvall O, Mummery C, Robey PG, Sattler de Sousa EBC, Smith A: Regulation of stem cell therapies under attack in europe: for whom the bell tolls. EMBO J 2013;32:1489-1495.
52.
Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R: Mesenchymal stem cells for clinical application. Vox Sang 2010;98:93-107.
53.
Cyranoski D: Korean deaths spark inquiry. Nature 2010;468:485.
54.
Tuffs A: Stem cell treatment in germany is under scrutiny after child's death. Br Med J 2010;341
55.
Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen SE, Fleischmann BK: Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007;110:1362-1369.
56.
Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F: Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007;21:304-310.
57.
Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd: Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011;29:11-19.
58.
Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M: Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 2008;43:1018-1023.
59.
Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Sensebe L, Keating A: Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010;12:576-578.
60.
Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebe L: Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010;115:1549-1553.
61.
Bieback K, Kinzebach S, Karagianni M: Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2011;2010:193519.
62.
Sensebe L: Clinical grade production of mesenchymal stem cells. Biomed Mater Eng 2008;18(1 suppl):S3-10.
63.
EMEA, Committee for Advanced Therapies (CAT): Reflection Paper on Stem Cell-Based Medicinal Products. EMA/CAT/571134, 2011. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500101692.pdf.
64.
EMEA, Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Medicinal Products. EMEA CPMP/BWP/1793/02, 2003. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003675. pdf.
65.
Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, Miller-Podraza H, Blomqvist M, Olonen A, Salo H, Lehenkari P, Tuuri T, Otonkoski T, Natunen J, Saarinen J, Laine J: N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007;25:197-202.
66.
Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK: Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001;97:1227-1231.
67.
Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ: Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004;9:747-756.
68.
Mannello F, Tonti GA: Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells 2007;25:1603-1609.
69.
Tekkatte C, Gunasingh GP, Cherian KM, Sankaranarayanan K: ‘Humanized' stem cell culture techniques: the animal serum controversy. Stem Cells Int 2011;2011:504723.
70.
Kinzebach S, Bieback K: Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions. Adv Biochem Eng Biotechnol 2013;129:33-57.
71.
Kilian O, Flesch I, Wenisch S, Taborski B, Jork A, Schnettler R, Jonuleit T: Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. Eur J Med Res 2004;9:337-344.
72.
Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G: Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets 2004;15:29-35.
73.
Kocaoemer A, Kern S, Klüter H, Bieback K: Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007;25:1270-1278.
74.
Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Kluter H: Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009;27:2331-2341.
75.
Muller AM, Davenport M, Verrier S, Droeser R, Alini M, Bocelli-Tyndall C, Schaefer DJ, Martin I, Scherberich A: Platelet lysate as a serum substitute for 2d static and 3d perfusion culture of stromal vascular fraction cells from human adipose tissue. Tissue Eng Part A 2009;15:869-875.
76.
Bernardo ME, Cometa AM, Pagliara D, Vinti L, Rossi F, Cristantielli R, Palumbo G, Locatelli F: Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol 2011;24:73-81.
77.
Fekete N, Gadelorge M, Furst D, Maurer C, Dausend J, Fleury-Cappellesso S, Mailander V, Lotfi R, Ignatius A, Sensebe L, Bourin P, Schrezenmeier H, Rojewski MT: Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: Production process, content and identification of active components. Cytotherapy 2012;14:540-554.
78.
Schrezenmeier H, Seifried E: Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010;99:1-15.
79.
Rauch C, Feifel E, Amann EM, Spotl HP, Schennach H, Pfaller W, Gstraunthaler G: Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. Altex-Altern Anim Ex 2011;28:305-316.
80.
Avanzini MA, Bernardo ME, Cometa AM, Perotti C, Zaffaroni N, Novara F, Visai L, Moretta A, Del Fante C, Villa R, Ball LM, Fibbe WE, Maccario R, Locatelli F: Generation of mesenchymal stromal cells in the presence of platelet lysate: A phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 2009;94:1649-1660.
81.
Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D: Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007;47:1436-1446.
82.
Crespo-Diaz R, Behfar A, Butler GW, Padley DJ, Sarr MG, Bartunek J, Dietz AB, Terzic A: Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 2011;20:797-811.
83.
Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, de Silvestri A, Amendola G, Zuffardi O, Maccario R, Locatelli F: Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007;211:121-130.
84.
Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR: Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol 2007;213:18-26.
85.
Schallmoser K, Strunk D: Preparation of pooled human platelet lysate (phpl) as an efficient supplement for animal serum-free human stem cell cultures. J Vis Exp 2009;(32).pii: 1523. doi: 10.3791/1523.
86.
Rojewski MT, Fekete N, Baila S, Nguyen K, Furst D, Antwiler D, Dausend J, Kreja L, Ignatius A, Sensebe L, Schrezenmeier H: GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant 2012; http://dx.doi.org/10.3727/096368912X657990.
87.
Nold P, Brendel C, Neubauer A, Bein G, Hackstein H: Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun 2013;430:325-330.
88.
Salvade A, Della Mina P, Gaddi D, Gatto F, Villa A, Bigoni M, Perseghin P, Serafini M, Zatti G, Biondi A, Biagi E: Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods 2010;16:201-214.
89.
Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, Brinchmann JE, Collas P: Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol 2008;52:1033-1042.
90.
Bocelli-Tyndall C, Zajac P, Di Maggio N, Trella E, Benvenuto F, Iezzi G, Scherberich A, Barbero A, Schaeren S, Pistoia V, Spagnoli G, Vukcevic M, Martin I, Tyndall A: Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class ii major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010;62:3815-3825.
91.
Flemming A, Schallmoser K, Strunk D, Stolk M, Volk HD, Seifert M: Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol 2011;31:1143-1156.
92.
Abdelrazik H, Spaggiari GM, Chiossone L, Moretta L: Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 2011;41:3281-3290.
93.
Bieback K, Ha VA, Hecker A, Grassl M, Kinzebach S, Solz H, Sticht C, Kluter H, Bugert P: Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A 2010;16:3467-3484.
94.
Dreher L, Elvers-Hornung S, Brinkmann I, Huck V, Henschler R, Gloe T, Kluter H, Bieback K: Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. Stem Cells Dev 2013;22:791-803.
95.
Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvade A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E: Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010;16:1293-1301.
96.
Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ: Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
97.
Dozza B, Di Bella C, Lucarelli E, Giavaresi G, Fini M, Tazzari PL, Giannini S, Donati D: Mesenchymal stem cells and platelet lysate in fibrin or collagen scaffold promote non-cemented hip prosthesis integration. J Orthop Res 2011;29:961-968.
98.
Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, Bierling P, Hernigou P, Layrolle P, Rouard H: Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials 2010;31:270-278.
99.
Centeno CJ, Schultz JR, Cheever M, Freeman M, Faulkner S, Robinson B, Hanson R: Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 2011;6:368-378.
100.
Lange C, Brunswig-Spickenheier B, Eissing L, Scheja L: Platelet lysate suppresses the expression of lipocalin-type prostaglandin d2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells. Exp Cell Res 2012;318:2284-2296.
101.
Murphy MB, Blashki D, Buchanan RM, Yazdi IK, Ferrari M, Simmons PJ, Tasciotti E: Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials 2012;33:5308-5316.
102.
Lohmann M, Walenda G, Hemeda H, Joussen S, Drescher W, Jockenhoevel S, Hutschenreuter G, Zenke M, Wagner W: Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One 2012;7:e37839.
103.
Senzel L, Gnatenko DV, Bahou WF: The platelet proteome. Curr Opin Hematol 2009;16:329-333.
104.
Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V: PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): Transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008;112:295-307.
105.
Perez-Ilzarbe M, Diez-Campelo M, Aranda P, Tabera S, Lopez T, del Canizo C, Merino J, Moreno C, Andreu EJ, Prosper F, Perez-Simon JA: Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion 2009;49:1901-1910.
106.
Janetzko K, Bugert P: Pathogen reduction in blood products: what's behind these techniques? Transfus Med Hemother 2011;38:5-6.
107.
Stahle M, Carlsson B, Le Blanc K, Korsgren O, Knutson F: Photochemical pathogen inactivation of human serum enables its large-scale application in clinical cell transplantation. Vox Sang 2010;98:e364-365.
108.
Shih DT, Chen JC, Chen WY, Kuo YP, Su CY, Burnouf T: Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate. Transfusion 2011;51:770-778.
109.
Von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M: Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009;43:245-251.
110.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.